Novocure (NVCR) shares gained nearly 2% pre-market after announcing positive topline results for its metastatic pancreatic cancer therapy. The Phase 2 PANOVA-4 trial met its primary endpoint, showing a statistically significant improvement in disease control rates. Retail sentiment on Stocktwits trended neutral despite the stock trending on the platform.